( MENAFN - EIN Presswire) Cold Agglutinin Disease Market Forecast DelveInsight's Cold Agglutinin Disease Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. NEVADA, LAS VEGAS, UNITED STATES, May 25, 2024 /EINPresswire / -- DelveInsight's“Cold Agglutinin Disease Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Cold Agglutinin Disease, historical and forecasted epidemiology as well as the Cold Agglutinin Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Cold Agglutinin Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cold Agglutinin Disease Market Forecast Some of the key facts of the Cold Agglutinin Disease Market Report: The Cold Agglutinin Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032) In January 2024, In a Phase 1 clinical trial, Annexon Biosciences' experimental oral therapy, ANX1502, designed for autoimmune conditions like cold agglutinin disease (CAD), achieved the targeted blood levels when administered twice daily to healthy volunteers.
ANX1502, delivered as a liquid suspension, was well-received with no significant adverse effects reported. The pharmacokinetics of ANX1502, detailing its distribution, metabolism, and elimination from the body, also indicated the feasibility of im.
